Skip to main content

Growth Hormone Deficiency SkyPass

The goal of this study is to further characterise the potential long-term safety risks of lonapegsomatropin in patients treated with lonapegsomatropin under real-world conditions in the post-marketing setting.

Gnanagurudasan Prakasam
Gnanagurudasan Prakasam
Principal investigator
View Profile

You're leaving our site

The website you have selected is an external one located on another server. This website may contain links to third party sites. These links are provided for convenience purposes and are not under the control of Sutter Health. Do you wish to continue?